ReviewThe American journal of gastroenterology2015
Medical marijuana for digestive disorders: high time to prescribe?
Review in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns.World journal of clinical cases · 2023Review
- A primer on common supplements and dietary measures used by patients with inflammatory bowel disease.Therapeutic advances in chronic disease · 2023Review
- Chronic delta-9-tetrahydrocannabinol (THC) treatment counteracts SIV-induced modulation of proinflammatory microRNA cargo in basal ganglia-derived extracellular vesicles.Journal of neuroinflammation · 2022Article
- Weight stability in adults with obesity initiating medical marijuana treatment for other medical conditions.Journal of cannabis research · 2022Article
- Effects of Δ9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review.International journal of environmental research and public health · 2022Review
- Preadmission Cannabis Use Is Positively Correlated With Inpatient Opioid Dose Exposure in Hospitalized Patients With Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2021Article
- Prevalence of cannabinoid hyperemesis syndrome and its financial burden on the health care industry.Proceedings (Baylor University. Medical Center) · 2021Article
- Insights into the role of cannabis in the management of inflammatory bowel disease.Therapeutic advances in gastroenterology · 2019Review
- Is There an Effect of Cannabis Consumption on Acute Pancreatitis?Digestive diseases and sciences · 2018Article
- miR-130a and miR-212 Disrupt the Intestinal Epithelial Barrier through Modulation of PPARγ and Occludin Expression in Chronic Simian Immunodeficiency Virus-Infected Rhesus Macaques.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review.Journal of ophthalmology · 2018Review
- Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.Journal of Crohn's & colitis · 2017Article
- Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.Journal of pediatric gastroenterology and nutrition · 2017Article
- Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.Inflammatory bowel diseases · 2017Review
- Severity and outcomes of acute alcoholic pancreatitis in cannabis users.Translational gastroenterology and hepatology · 2017Article
- Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids.Frontiers in molecular neuroscience · 2017Article
- Article
- Article
- Therapeutic Use of Cannabis in Inflammatory Bowel Disease.Gastroenterology & hepatology · 2016Article
- Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids.Autophagy · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of recreational and medical marijuana is increasingly accepted by the general public in the United States. Along with growing interest in marijuana use has come an understanding of marijuana's effects on normal physiology and disease, primarily through elucidation of the human endocannabinoid system. Scientific inquiry into this system has indicated potential roles for marijuana in the modulation of gastrointestinal symptoms and disease. Some patients with gastrointestinal disorders already turn to marijuana for symptomatic relief, often without a clear understanding of the risks and benefits of marijuana for their condition. Unfortunately, that lack of understanding is shared by health-care providers. Marijuana's federal legal status as a Schedule I controlled substance has limited clinical investigation of its effects. There are also potential legal ramifications for physicians who provide recommendations for marijuana for their patients. Despite these constraints, as an increasing number of patients consider marijuana as a potential therapy for their digestive disorders, health-care providers will be asked to discuss the issues surrounding medical marijuana with their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.